The research team embarked on an extensive examination of more than 2,600 neuroimaging scans from adult participants aged between 30 and 97 years. This comprehensive dataset allowed them to systematically map age-dependent shifts in brain topology rather than merely measuring volumetric reductions. Remarkably, they identified that the inferior (lower) and anterior (front) brain regions underwent expansion, while the superior (upper) and posterior (back) areas contracted. These shape modifications were not uniform but exhibited pronounced asymmetry in individuals exhibiting diminished cognitive abilities, such as impaired reasoning and memory. These correlations provide compelling evidence linking mechanical brain deformation with functional neurodegeneration.

Stepwise geometric alterations elucidated by this study reflect broader biological phenomena underpinning brain aging. One of the most compelling findings is the localized compression of posterior brain regions, phenomena hypothesized to exert physical pressure on crucial neural hubs. Notably, the entorhinal cortex—a small but pivotal structure within the medial temporal lobe implicated in memory consolidation—appears especially vulnerable. This region bears early accumulations of tau proteins, pathogenic agents heavily implicated in Alzheimer’s disease. The physical displacement of the entorhinal cortex closer to the rigid base of the skull suggests that mechanical and gravitational forces may significantly contribute to Alzheimer’s pathogenesis, an insight that broadens existing disease models which focus predominantly on molecular cascades.

“This discovery is a paradigm shift in understanding brain aging,” said Dr. Niels Janssen, senior author and professor at Universidad de La Laguna, also a visiting scholar at UCI’s CNLM. “Our data emphasize that it is not just how much brain tissue is lost, but how the overall brain geometry is remodeled systematically over time, fundamentally reshaping our view of neurodegenerative vulnerability.” Importantly, these shape biomarkers were independently validated in two separate datasets, reinforcing their reproducibility and robustness.

The mechanistic link between brain shape distortion and cognitive decline raises profound questions about the interplay of mechanical forces, tissue stress, and neurodegeneration. Dr. Michael Yassa, director of the CNLM and co-author, elaborates, “As the aging brain subtly shifts, it may increasingly pinch the fragile entorhinal cortex against the inflexible cranial base, potentially fostering an environment conducive to early pathological protein aggregation and neuronal loss.” This mechanical hypothesis introduces an underexplored dimension to Alzheimer’s research, advocating for multidisciplinary inquiries combining neuroanatomy, biomechanics, and molecular neuroscience.

The implications of this work extend well beyond academic curiosity. Geometric analysis of brain morphology could pioneer new avenues for early dementia risk identification. Current diagnostic modalities largely detect pathology after considerable cognitive impairment occurs, often relying on volumetric brain atrophy or molecular imaging techniques. In contrast, shape-based metrics derived from standard brain imaging could serve as non-invasive, accessible, and early indicators of neurodegenerative risk, potentially enabling interventions during preclinical stages when therapies might be most effective.

Beyond the entorhinal cortex, the observed macroscopic alterations in brain regions influence networks underlying memory, reasoning, and executive function. The flattening and inward contraction of posterior structures corresponded robustly with poorer performance on reasoning tasks among older adults. Thus, the spatial reconfiguration of the brain does not merely reflect passive aging but appears intricately linked to functional cognitive outcomes, highlighting the integral relationship between form and function in the human brain.

This pioneering work benefits from an international collaboration between UCI and Universidad de La Laguna, exemplifying how scientific progress is accelerated by cross-border partnerships. The multidisciplinary team integrated expertise in neuroimaging, computational analysis, aging neuroscience, and cognitive assessment, enabling comprehensive synthesis of complex, large-scale data into novel biological insights. The study underscores the critical importance of combining technical innovation with collaborative scholarship to address one of the most pressing public health challenges: dementia and neurodegeneration.

Looking ahead, the team is optimistic that the geometric approach could inspire new diagnostic and therapeutic strategies. By charting how architectural brain changes unfold before symptoms emerge, researchers can better stratify individuals by risk and tailor interventions more precisely. Further research will focus on elucidating the molecular and biomechanical underpinnings of these shape changes, potentially revealing modifiable factors that could mitigate or delay cognitive decline.

The study, published in the prestigious journal Nature Communications, was funded by the National Institute on Aging. It represents a significant leap in our understanding of brain aging, emphasizing that morphology—and not merely volume loss—should be considered a fundamental metric in neuroscience research. As Dr. Yassa poignantly concludes, “The answers to Alzheimer’s and other neurodegenerative diseases may be hiding in plain sight—in the very shape of the brain.”

In a landscape dominated by attempts to decode the molecular intricacies of dementia, this research invites a fresh vantage point that integrates structural brain dynamics with disease vulnerability. The findings call for renewed attention toward biomechanical and geometric factors and open exciting possibilities for innovative diagnostic tools that could transform clinical practice. Through such integrative science, we move closer to unraveling the complexity of brain aging and developing effective strategies to preserve cognitive health in our aging populations.

Subject of Research: Brain geometry changes related to aging and cognitive decline

Article Title: Age-related constraints on the spatial geometry of the brain

News Publication Date: October 1, 2025

Web References:

• Study article in Nature Communications: https://rdcu.be/eIKAu
• Larger research effort: http://beacon.bio.uci.edu/
• UC Irvine website: http://www.uci.edu
• UC Irvine News: http://news.uci.edu/
• Media Resources: https://news.uci.edu/media-resources/

References: Published article in Nature Communications, supported by National Institute on Aging

Keywords: Health and medicine, brain aging, neurodegeneration, Alzheimer’s disease, entorhinal cortex, brain morphology, cognitive decline

Alzheimer’s disease, a progressive neurodegenerative disorder marked by cognitive deterioration and memory loss, poses a significant challenge for early diagnosis, particularly in underserved populations. Current diagnostic standards often rely on neuroimaging or cerebrospinal fluid analysis, which are invasive, expensive, and inaccessible to many. The FDA-approved blood assay currently in use, the Lumipulse G pTau217/Aβ42 plasma ratio, although accurate, remains a specialized and costly option, limiting its widespread utility. This backdrop emphasizes the need for scalable diagnostic alternatives.

The UC San Diego research team leveraged extensive data from the Hispanic Community Health Study/Study of Latinos (HCHS/SOL), the most comprehensive long-term study focusing on Hispanic and Latino health in the United States, to explore the viability of blood biomarkers as indicators of neurodegenerative processes. This particular effort zeroed in on a subset of 5,712 Hispanic and Latino adults aged 50 to 86, making it one of the largest biomarker studies conducted within this demographic.

Subjective cognitive decline, a self-perceived reduction in cognitive capacity such as memory or executive function, was used as a critical clinical endpoint. The researchers assessed concentrations of various proteins in participants’ plasma, focusing on amyloid beta (Aβ42/40), tau proteins, neurofilament light chain (NfL), and glial fibrillary acidic protein (GFAP). These molecules are implicated in neuronal injury, brain inflammation, and hallmark pathological processes in Alzheimer’s disease pathology.

Remarkably, the analysis revealed that elevated plasma levels of NfL and GFAP were associated with higher reports of declines in complex cognitive tasks including planning and overall cognitive performance. Furthermore, increased NfL and phosphorylated tau protein (ptau-181) correlated with self-reported memory impairments. These findings underscore the potential utility of these markers as proxies for neurodegeneration and neuroinflammation reflective of Alzheimer’s pathology.

Contrary to expectations, amyloid-beta levels in blood, a classic pathological hallmark of Alzheimer’s in the brain, did not show a significant relationship with self-reported cognitive decline. This disconnect highlights ongoing challenges in translating amyloid assays from brain-centric pathology to peripheral biomarkers and invites further investigation into the temporal and mechanistic underpinnings of amyloid dynamics in plasma.

One of the study’s most intriguing findings rests on the data from cognitively unimpaired individuals. Even among participants without clinically detectable cognitive deficits, elevated NfL levels were linked to subtle self-perceived cognitive declines, fortifying the hypothesis that NfL could serve as an early sentinel biomarker. This emphasizes a vital potential clinical application: identifying individuals at risk before extensive neuronal damage occurs.

The inclusion of Hispanic and Latino participants fills a critical gap in Alzheimer’s research, addressing a population historically underrepresented despite exhibiting higher prevalence rates and projected increases in dementia incidence. By analyzing biomarker-cognition relationships within this diverse group, the study offers valuable insight into how social determinants of health, genetic predispositions, and comorbidities may modulate disease progression and biomarker expression.

Moreover, this research advocates for blood-based biomarkers as scalable tools capable of extending diagnostic reach beyond specialized centers. The relative simplicity and affordability of blood tests could revolutionize screening strategies, especially in resource-limited and diverse clinical settings. Nonetheless, the authors caution that these biomarkers should complement, rather than replace, existing diagnostic methods until further validation solidifies their clinical utility.

The complexity of Alzheimer’s pathogenesis and heterogeneity in clinical presentation necessitate a multifaceted diagnostic approach. Biomarkers such as NfL and GFAP reflect neuroaxonal damage and gliosis, respectively, capturing critical components of neurodegeneration but may not encompass the full spectrum of pathological features. Integrating biomarker data with cognitive assessments and imaging will remain essential in crafting comprehensive diagnostic frameworks.

Funded in part by grants from the National Institute on Aging and supported through collaborative efforts involving multiple universities, this study exemplifies the power of multi-institutional research endeavors focused on health equity. The inclusion of investigators from University of North Carolina, Wayne State University, San Diego State University, University of Miami, University of Illinois at Chicago, University of Minnesota, and University of California campuses underscores the initiative’s breadth.

While promising, the translation of blood-based biomarker assays into routine clinical practice faces several hurdles including assay standardization, cost reduction, regulatory approval, and integration into clinical decision-making processes. The study’s authors emphasize that ongoing research is crucial to ascertain biomarkers’ predictive validity, especially in diverse populations, and to understand their longitudinal dynamics in relation to cognitive trajectories.

This advancement marks a hopeful step toward democratizing Alzheimer’s diagnostics, potentially enabling earlier interventions that could alter disease course or improve quality of life. By harnessing blood-based biomarker technologies in previously understudied populations, the scientific community moves closer to more inclusive and effective strategies combating the global burden of Alzheimer’s disease.

Subject of Research: Blood-based biomarkers for early detection of Alzheimer’s disease and cognitive decline in Hispanic and Latino adults

Article Title: Not specified in the provided content

News Publication Date: Not specified in the provided content

Web References: https://doi.org/10.1001/jamanetworkopen.2025.31038

Keywords: Alzheimer disease, Cognitive disorders, Blood, Medical diagnosis